

**In the Claims**

1. (Currently amended) A method for ~~modulating an immune response~~ decreasing regulatory CD4+ T cell activity comprising administering exposing a regulatory CD4+ T cell to a modulator of Notch intracellular domain (Notch IC) protease activity, wherein the modulator is an inhibitor of presenilin or of presenilin-dependent gamma-secretase.
2. (Cancelled)
3. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the presenilin is Presenilin-1 (PS1) or Presenilin-2 (PS2).
4. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the ~~agonist~~ inhibitor is selected from the group consisting of polypeptides, fragments thereof, linear peptides, cyclic peptides, nucleic acids encoding therefor, synthetic compounds, natural compounds, low molecular weight organic compounds, low molecular weight inorganic compounds and antibodies.
5. (Currently amended) The method of claim 1, further comprising ~~administering a modulator of~~ exposing the regulatory CD4+ T cell to an agent that down-regulates the Notch signalling pathway.
- 6-11. (Cancelled)
12. (Currently amended) The method of ~~claim 11~~ claim 1, wherein the ~~agonist~~ inhibitor of presenilin is 26S proteasome or Sel 10 or a nucleic acid sequence encoding therefor.
13. (Cancelled)
14. (Currently amended) The method of ~~claim 11~~ claim 5, wherein the agent that down-regulates the Notch signalling pathway is a polypeptide selected from the group consisting of a Toll-like receptor, a cytokine, a bone morphogenetic protein (BMP), a BMP receptor and an activin, or is a nucleic acid sequence encoding therefor.
15. (Cancelled)
16. (Currently amended) The method of ~~claim 15, wherein the~~ claim 1, further comprising administering a selected antigen or antigenic determinant, or a nucleic acid encoding the antigen or antigenic determinant, ~~is administered~~ simultaneously, contemporaneously, separately or sequentially with the modulator.
17. (Currently amended) The method of ~~claim 15~~ claim 16, wherein the antigen or antigenic determinant is a tumour antigen or antigenic determinant or an antigen or antigenic

determinant of a pathogen.

18-29. (Cancelled)

30. (Currently amended) The method of ~~claim 19~~ claim 1, wherein the regulatory CD4+ T-cell is a Tr1 regulatory T-cell.

31. (Cancelled)

32. (Cancelled)

33. (Currently amended) The method of ~~claim 19~~ claim 1, wherein the regulatory CD4+ T-cell is a Th3 regulatory T-cell.

34. (Cancelled)

35. (Cancelled)

36. (Original) The method of claim 1, wherein the modulator is administered to a subject in vivo.

37. (Withdrawn) The method of claim 1, wherein the modulator is administered to a cell ex vivo.

38-41. (Cancelled)

42. (Currently amended) A method for modulating cytokine expression in regulatory CD4+ T cells comprising administering exposing a regulatory CD4+ T cell to a modulator of Notch intracellular domain (Notch IC) protease activity, wherein the modulator is an inhibitor of presenilin or of presenilin-dependent gamma-secretase.

43-46. (Cancelled)

47. (Currently amended) The method of ~~claim 46~~ claim 42, wherein the cytokine is IL-10 or IL-4, ~~wherein the modulator is an inhibitor of Notch IC protease activity~~, and wherein expression of the cytokine is decreased.

48. (Cancelled)

49. (Currently amended) The method of ~~claim 46~~ claim 47, wherein the cytokine is IL-10.

50. (Currently amended) The method of ~~claim 46~~ claim 47, wherein the cytokine is IL-4.

51. (Currently amended) The method of ~~claim 46~~ claim 42, wherein the cytokine is IL-2, IL-5, TNF-alpha, IFN-gamma or IL-13, ~~wherein the modulator is an inhibitor of Notch IC~~

~~protease activity~~, and wherein expression of the cytokine is increased.

52. (Cancelled)
53. (Currently amended) The method of ~~claim 46~~ claim 51, wherein the cytokine is IL-2.
54. (Currently amended) The method of ~~claim 46~~ claim 51, wherein the cytokine is IL-5.
55. (Currently amended) The method of ~~claim 46~~ claim 51, wherein the cytokine is TNF-alpha.
56. (Currently amended) The method of ~~claim 46~~ claim 51, wherein the cytokine is IFN-gamma.
57. (Currently amended) The method of ~~claim 46~~ claim 51, wherein the cytokine is IL-13.
58. (Cancelled)
59. (Cancelled)
60. (Currently amended) The method of ~~claim 46, wherein the modulator is an inhibitor of Notch IC protease activity, and~~ claim 42, wherein IL-10 expression is decreased and IL-5 expression is increased.
61. (Currently amended) The method of ~~claim 46, wherein the modulator is an inhibitor of Notch IC protease activity, and~~ claim 42, wherein IL-10 expression is decreased and IL-2, IFN-gamma, IL-5, IL-13 and TNF-alpha expression are increased.
- 62-64. (Cancelled)
65. (Original) The method of claim 42, wherein the modulator is administered to a subject in vivo.
66. (Withdrawn) The method of claim 42, wherein the modulator is administered to a cell ex vivo.
- 67-99. (Cancelled)
100. (Currently amended) The method of ~~claim 98~~ claim 1, wherein the inhibitor is a small molecule inhibitor.
101. (Currently amended) The method of ~~claim 98~~ claim 100, wherein the inhibitor is MW167, having Formula I.